Preview Mode Links will not work in preview mode

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Jun 11, 2024

The most common congenital heart defect, congenital BAV, affects 1% of the population (2% in men, 0.5% in women), with a male-to-female ratio of 2:1 to 3:1. It's characterized by diverse phenotypic expressions and outcomes, falling into two prognostic groups: 

  1. Typical valvulo-aortopathy: Most common, with...


Jun 4, 2024

Discover how detection of coronary artery calcium can greatly enhance risk prediction and risk mitigation, making it a critical tool for clinicians aiming to personalize patient care and prevent future cardiac events. 

In this interview, Michael D. Shapiro, DO, FACC and Roger S. Blumenthal MD, FACC explore CAC...


May 28, 2024

In this interview, Leslie Cho, MD, FACC, and Steven E. Nissen MD, MACC explore the nuances of estrogen and testosterone replacement: who benefits, when to consider it, and how long it should last. 

 

 


May 21, 2024

Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.

In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results...


May 14, 2024

The Be Active trial demonstrates the efficacy of scalable interventions, incorporating remote monitoring and behavioral economics, in boosting physical activity among high-risk cardiovascular patients. Lasting effects were observed even six months post-intervention. While additional data may be warranted for some...